InvestorsHub Logo
Followers 0
Posts 596
Boards Moderated 0
Alias Born 05/15/2017

Re: None

Monday, 10/21/2019 10:50:40 AM

Monday, October 21, 2019 10:50:40 AM

Post# of 197512
(ADMP) MC $33 M-FDA DECISION ON Oct.31...the most underpriced and hottest fda play for the year .. they have already a marketed drug partnered with Sanodz (Novartis) which targeting a $1.5 BILLION market the drug was full lauchned in Q2 this year = POTENTIAL 10 BAGGER HERE GUYS ..


Admamis Pharma (ADMP)

Market-Cap:$33 million
Cash: $17 million
Price: $0.54


Presentation
http://ir.adamispharmaceuticals.com/static-files/63eff6dd-0286-457e-a959-920540f0cdb1



ZIMHI (naloxone) injection

Indication–Opioid Overdose

Addressable Market -$330 million

FDA action date Oct. 31, 2019




SYMJEPI (epinephrine) injection

Indication-Anaphylaxis

Addressable Market -$1.5 billion

Launched–January 2019


First products using patented, FDA-approved injection device
Both doses (0.3mg and 0.15mg) are FDA approved

Sandoz a division of Novartis –commercial partner in U.S.

Commercial deal terms –50% of net profits, upfront fee and potential performance-based milestone payments




Near-Term Target Milestones

FDA action date (PDUFA) of Oct. 31, 2019 on NDA for ZIMHI

Pursuing potential partnerships for SYMJEPI (ex-US) and ZIMHI product candidate

Continued launch of SYMJEPI in U.S. –retail and SYMJEPI low dose launches pending

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.